# Obexelimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/obexelimab

> The PDUFA target action date for obexelimab, sponsored by Zenas BioPharma, Inc. (ZBIO), is May 27, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the obexelimab PDUFA date?

The PDUFA target action date for obexelimab, sponsored by Zenas BioPharma, Inc. (ZBIO), is May 27, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 -" Last confirmed November 6, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/obexelimab)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-123035, https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-06. Cite: https://sec-api.dev/pdufa/obexelimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | obexelimab |
| Codes |  |
| Sponsor | Zenas BioPharma, Inc. (ZBIO) https://sec-api.dev/companies/zbio/catalysts |
| Indications | igg4-rd, igg4-rd in may 2026, igg4-rd in second quarter 2026 -, [immunoglobulin g4-related disease](https://sec-api.dev/indications/immunoglobulin-g4-related-disease), Warm Autoimmune Hemolytic Anemia, [Relapsing Multiple Sclerosis](https://sec-api.dev/indications/relapsing-multiple-sclerosis), [Systemic Lupus Erythematosus](https://sec-api.dev/indications/systemic-lupus-erythematosus) |
| Modality | antibody |
| FDA designations | orphan |

## Timeline

### August 28, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06564311 (A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT06564311

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-05-15, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "The Company expects to report topline results from this trial, including the 12-week primary endpoint results, early in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109737): "- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925109737/tm2530850d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-102317): "Zenas also expects to report topline results from the obexelimab Phase 3 INDIGO trial in IgG4-RD around year-end 2025 and topline results from the" https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "In the fourth quarter of 2024, we completed the target enrollment of our registration-directed Phase 3 trial (the "INDIGO" trial) for obexelimab as a treatment for IgG4-RD, and we expect to report topline results from the INDIGO trial around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109737): "We look forward to sharing topline results from the obexelimab Phase 3 INDIGO trial in IgG4-RD around year-end."" https://www.sec.gov/Archives/edgar/data/1953926/000110465925109737/tm2530850d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): ""We are pleased with the continued momentum of our obexelimab program across ongoing Phase 2 and Phase 3 clinical trials, for which we expect to report topline results later this year from trials in patients with relapsing multiple sclerosis and IgG4-RD," said Lonnie Moulder, Founder and Chief Executive Officer of Zenas." https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm

### November 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: IgG4 Related Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05662241 (A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT05662241

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: IgG4-RD.
- First seen 2026-01-05, last confirmed 2026-08-13.
- SEC Form 8-K (accession 0001104659-26-000402): "Following the positive Phase 3 INDIGO results, the Company anticipates submitting a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for obexelimab in IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926000402/tm261774d1_8k.htm
- SEC Form 10-Q (accession 0001104659-26-059735): "Based on these results, we plan to submit the obexelimab Biologics License Application to the FDA for the treatment of IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926059735/zbio-20260331x10q.htm
- SEC prospectus (424B) (accession 0001104659-26-036534): "Based on these results, we plan to submit the obexelimab Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for the treatment of IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036534/tm261753-10_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-036536): "Based on these results, we plan to submit the obexelimab Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for the treatment of IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036536/tm261753-11_424b5.htm
- SEC Form 10-K (accession 0001104659-26-027964): "Based on these results, we plan to submit the obexelimab Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for the treatment of IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-027964): "Based on these results, we plan to submit the obexelimab BLA to the FDA for the treatment of IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-027964): "Following the positive Phase 3 INDIGO results, we anticipate submitting a BLA to the FDA for obexelimab in IgG4-RD in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-027961): "Zenas expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the" https://www.sec.gov/Archives/edgar/data/1953926/000110465926027961/tm268878d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-000402): "- Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA)" https://www.sec.gov/Archives/edgar/data/1953926/000110465926000402/tm261774d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-000402): "We look forward to submitting our Biologics License Application to the FDA in the second quarter of 2026 and our Marketing Authorization Application to the EMA in the second half of this year."" https://www.sec.gov/Archives/edgar/data/1953926/000110465926000402/tm261774d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095437): "Zenas intends to submit a supplemental application to obexelimab's IgG4-RD BLA, if approved, and to include the single-dose prefilled pen and bioequivalence data in a European MAA submission in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059700): "Obexelimab marketing applications for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD) remain on track: Zenas expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) this quarter and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm

### mid-2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2026-03-30.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "around year-end 2025, and we expect to report topline results from the SunStone trial in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "Zenas expects to complete enrollment in this trial by year-end 2025 and report topline results in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116346): "SunStone remains on track to complete enrollment in 2025 and the Company expects to report topline results for SunStone in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076464): "Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-036534): "If the topline results are positive, we expect to file a Biologics License Application with the U.S. Food and Drug Administration in the first half of 2026, followed by a Marketing Authorization Application with the European Medicines Agency, and, if approved, commence the commercial launch initially in the United States and then in Europe." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036534/tm261753-10_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-036534): "We expect to complete enrollment in the SunStone trial by around year-end 2025 and to report topline results from the SunStone trial in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036534/tm261753-10_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-036536): "If the topline results are positive, we expect to file a Biologics License Application with the U.S. Food and Drug Administration in the first half of 2026, followed by a Marketing Authorization Application with the European Medicines Agency, and, if approved, commence the commercial launch initially in the United States and then in Europe." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036536/tm261753-11_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-036536): "We expect to complete enrollment in the SunStone trial by around year-end 2025 and to report topline results from the SunStone trial in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036536/tm261753-11_424b5.htm
- SEC Form 10-Q (accession 0001104659-25-109753): "We expect to report topline results from the SunStone trial in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925109753/zbio-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011147): "We expect to complete enrollment in the SunStone trial by year-end 2025 and to report topline results from the SunStone trial in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000155837025011147/zbio-20250630x10q.htm

### May 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: IgG4-RD in May 2026.
- First seen 2026-08-13, last confirmed 2026-11-06.
- SEC prospectus (424B) (accession 0001104659-26-123876): "Based on these results, we submitted the obexelimab Biologics License Application ("BLA") to the FDA for the treatment of IgG4-RD in May 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-123040): "Based on these results, we submitted the obexelimab Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for the treatment of IgG4-RD in May 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123040/zbio-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095448): "Based on these results, we submitted the obexelimab Biologics License Application ("BLA") to the FDA for the treatment of IgG4-RD in May 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095448/zbio-20260630x10q.htm

### June 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Warm Autoimmune Hemolytic Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05786573 (A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT05786573

### Aug 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-05, last confirmed 2026-11-06.
- SEC prospectus (424B) (accession 0001104659-26-123876): "In August 2026, the FDA accepted the Company's BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-123040): "In August 2026, the FDA accepted our BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123040/zbio-20260930x10q.htm

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06559163 (A Study of Obexelimab in Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT06559163

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Systemic Lupus Erythematosus.
- First seen 2025-08-12, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059700): "Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115151): "SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926115151/tm2627406d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-123040): "In April 2026, we completed enrollment in the SunStone trial and expect to report topline results, including biomarker data, in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123040/zbio-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095448): "In April 2026, we completed enrollment in the SunStone trial and expect to report topline results, including biomarker data, in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095448/zbio-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123035): "- Obexelimab global Phase 2 SunStone SLE trial topline results on track for fourth quarter 2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095437): "Beyond IgG4-RD, we are on track to report Phase 2 topline data for obexelimab in SLE and initial Phase 1 data for ZB021 by year-end." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109737): "Zenas expects to complete enrollment of the Phase 2 SunStone trial around year-end 2025 and report topline results in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925109737/tm2530850d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "Zenas expects to complete enrollment of the Phase 2 SunStone trial around year-end 2025 and report topline results in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076464): "Zenas expects to complete enrollment of the Phase 2 SunStone trial by year-end 2025 and report topline results in mid-2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095437): "Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059700): "- Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm
- ClinicalTrials.gov: "NCT06559163 (A Study of Obexelimab in Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT06559163

### May 27, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-13, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123035): "PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095437): "Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027" https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095437): ""2026 continues to be a transformative year for Zenas, highlighted by FDA acceptance of the obexelimab BLA for the treatment of IgG4-RD, with a PDUFA date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123035): "Fee Act (PDUFA) target action date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-123876): "In August 2026, the FDA accepted the Company's BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-123040): "In August 2026, the FDA accepted our BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123040/zbio-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095448): "In August, the FDA accepted the Company's BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095448/zbio-20260630x10q.htm

## Same indication

- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)
- [BLINCYTO® (blinatumomab)](https://sec-api.dev/pdufa/blinatumomab) (AMGN)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [UPLIZNA® (inebilizumab)](https://sec-api.dev/pdufa/inebilizumab) (AMGN)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [MK-6194](https://sec-api.dev/pdufa/mk-6194) (MRK)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) (NVS)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [Tolebrutinib](https://sec-api.dev/pdufa/tolebrutinib) (SNY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

Calendar months: [June 2026](https://sec-api.dev/fda-calendar/2026-06), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/obexelimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Obexelimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/obexelimab

```bibtex
@misc{secapidev_pdufa_obexelimab_20261116,
  title        = {Obexelimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/obexelimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_obexelimab_20261116","title":"Obexelimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/obexelimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
